1. Viscoelastic testing in benign hematologic disorders: Clinical perspectives and future implications of point‐of‐care testing to assess hemostatic competence
   Jacob Speybroeck et al, 2020, Transfusion CrossRef
2. Losing the forest for the trees: The complexities of fibrinolysis will never be explained with one variable alone
   Julia R. Coleman et al, 2024, Journal of Trauma and Acute Care Surgery CrossRef
3. Therapeutics targeting the fibrinolytic system
   Haili Lin et al, 2020, Experimental & Molecular Medicine CrossRef
4. Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1
   Stéphane Pautus et al, 2016, Scientific Reports CrossRef
5. Retracted: MicroRNA‐335‐5p suppresses lower extremity deep venous thrombosis by targeted inhibition of PAI‐1 via the TLR4 signalingpathway
   Cui‐Xia Bao et al, 2018, Journal of Cellular Biochemistry CrossRef
6. RUNX1 and TGF‐β signaling cross talk regulates Ca2+ ion channels expression and activity during megakaryocyte development
   Sanjeev Raghuwanshi et al, 2020, The FEBS Journal CrossRef
7. Role of Fibrinolytic Mechanisms in Breast Cancer Diagnosis, Prognosis, and Treatment
   Asma Saleem Qazi et al, 2022, Breast Cancer: From Bench to Personalized Medicine CrossRef
8. Temporary inhibition of the plasminogen activator inhibits periosteal chondrogenesis and promotes periosteal osteogenesis during appendicular bone fracture healing
   D. Bravo et al, 2018, Bone CrossRef
9. Identification of the multiple roles of enolase as an plasminogen receptor and adhesin in Mycoplasma hyopneumoniae
   Qingyun Xie et al, 2023, Microbial Pathogenesis CrossRef
10. Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke
    Rui Chen et al, 2017, Metabolic Brain Disease CrossRef